Introduction: the somatotropic axis in metabolic research

The growth hormone (GH) axis — comprising hypothalamic GHRH, pituitary somatotropes, and hepatic/peripheral IGF-1 production — is a central regulator of body composition, substrate metabolism, and adipose-tissue dynamics. GH promotes lipolysis in adipose tissue, stimulates hepatic IGF-1 synthesis, and has anabolic effects in skeletal muscle. Age-related decline in GH pulsatility (somatopause) contributes to the progressive accumulation of visceral fat and loss of lean mass characteristic of metabolic ageing. GHRH analogues such as tesamorelin and CJC-1295 are designed to restore youthful GH pulsatility rather than bypass the axis entirely — a mechanistic distinction with significant safety implications.

The GHRH peptide: structure and endogenous secretion

GHRH is synthesised predominantly by neurons in the arcuate nucleus of the hypothalamus and reaches anterior pituitary somatotropes via the hypothalamo-hypophyseal portal circulation. The bioactive form is GHRH(1-44)-NH₂ (44 amino acids, C-terminal amide), though GHRH(1-40)-OH is also present in human plasma. Secretion is episodic: GHRH pulses occurring at approximately 90–120-minute intervals drive the ultradian rhythm of pituitary GH release. Somatostatin (SRIF) — secreted from periventricular hypothalamic neurons — interacts reciprocally with GHRH pulses to gate the amplitude and timing of GH bursts.

Native GHRH has a circulating half-life of approximately 7 minutes, degraded primarily by plasma peptidases including DPP-4 at the His-Ala N-terminal bond and by tissue endopeptidases. This rapid clearance severely limits the utility of unmodified GHRH for therapeutic application.

GHRHR: receptor pharmacology and somatotrope signalling

The GHRH receptor (GHRHR) is a Class B G-protein-coupled receptor expressed predominantly on anterior pituitary somatotropes, with lower-level expression in peripheral tissues including the pancreas, adrenal gland, and gonads. Agonist binding to GHRHR couples through Gαs to adenylyl cyclase, elevating intracellular cAMP. cAMP activates PKA, which phosphorylates CREB (cAMP response element-binding protein) — the transcription factor driving GH gene expression and somatotrope proliferation. Simultaneously, PKA activation opens voltage-gated calcium channels in the somatotrope plasma membrane, providing the calcium influx necessary for GH vesicle exocytosis.

Critically, GHRHR activation does not override somatostatin inhibition: when somatostatin occupies its receptors (SSTR2, SSTR5) on the same somatotrope cell, Gαi-coupled adenylyl cyclase inhibition dominates and GH secretion is suppressed regardless of concurrent GHRHR stimulation. This gate-keeping mechanism is preserved by GHRH analogues and constitutes the primary safety argument for GHRHR agonism over exogenous GH.

Physiological GH pulsatility: why it matters

GH secretion in healthy young adults occurs in 6–12 discrete pulses per 24 hours. The dominant pulse coincides with slow-wave sleep (stages N3/N4), driven by a nocturnal GHRH surge suppressed somatostatin tone during early sleep. Between pulses, circulating GH returns to near-undetectable levels. This pulsatile pattern is biologically indispensable for several reasons:

Receptor sensitivity maintenance: Continuous GH elevation desensitises GH receptor (GHR) signalling through JAK2/STAT5 downregulation; pulsatile delivery allows receptor resensitisation between pulses.
Hepatic IGF-1 induction: Pulsatile GH is more potent than continuous GH at inducing hepatic IGF-1 gene transcription — the downstream anabolic effector of the axis.
Lipolytic efficiency: The burst pattern of lipolytic signalling through GHR/JAK2/IRS-1 in adipose tissue produces different substrate mobilisation dynamics than tonic stimulation, with pulsatile exposure favouring visceral fat mobilisation preferentially.

Exogenous recombinant GH (rhGH) administration — whether via injection or continuous subcutaneous infusion — fails to recapitulate this pulsatile pattern, producing supraphysiological sustained GH exposure that drives insulin resistance, fluid retention, and joint complaints not seen with GHRH-analogue-restored physiological pulses.

Tesamorelin: GHRH(1-44) stabilised for clinical use

Tesamorelin (brand name Egrifta in the United States, where it holds FDA approval for HIV-associated lipodystrophy) is a synthetic analogue of GHRH(1-44)-NH₂ incorporating a trans-3-hexenoic acid conjugation at the N-terminal tyrosine residue. This modification shields the His1-Ala2 dipeptide bond from DPP-4 cleavage and reduces susceptibility to other plasma peptidases, extending the effective half-life to approximately 26–38 minutes following subcutaneous injection — sufficient for reliable pituitary stimulation with daily or twice-daily administration.

Importantly, tesamorelin retains full biological activity at the GHRHR: in clinical studies it produces GH pulses that are physiologically shaped — occurring during the normal nocturnal window and maintaining appropriate pulse width and amplitude — rather than inducing flat supraphysiological GH elevation. IGF-1 levels rise into the upper-normal range, rather than exceeding it.

See the tesamorelin profile for dosing, clinical data, and metabolic applications in detail.

CJC-1295: albumin binding for once-weekly GHRH agonism

CJC-1295 (also designated DAC:GRF) extends GHRH analogue technology by incorporating the Drug Affinity Complex (DAC) — a maleimido-propionic acid (MPA) moiety at Lys-30 that covalently binds the thiol group of Cys-34 on circulating albumin. This covalent albumin conjugation confers a plasma half-life of approximately 6–8 days, transforming a peptide with a 7-minute native half-life into a compound suitable for once-weekly subcutaneous dosing.

The pharmacokinetic consequence is a sustained, low-amplitude increase in the GHRH signal reaching pituitary somatotropes — described in Phase 2 studies as producing "GH waves" rather than discrete pulses. This differs from the pulsatile pattern generated by tesamorelin and raises the question of whether albumin-conjugated GHRH analogues fully recapitulate physiological pulsatility or instead produce a hybrid pattern. Clinical data from CJC-1295 Phase 2 trials demonstrated mean IGF-1 increases of 44–170% above baseline depending on dose, sustained for the dosing interval, consistent with the prolonged GHRHR stimulation model.

CJC-1295 is commonly combined in clinical research formulations with ipamorelin (a GHSR agonist) to provide synergistic somatotrope stimulation through two independent receptor pathways. See the GHSR/ghrelin mechanism guide and the CJC-1295/ipamorelin profile for details on this combination.

GHRH analogues vs exogenous GH: the axis-preservation argument

The central mechanistic advantage of GHRH analogues over exogenous rhGH administration is that the pituitary and its regulatory feedback network remain in the signalling loop. Somatostatin feedback from rising IGF-1 levels acts directly on pituitary somatotropes and hypothalamic GHRH neurons to limit GH output; the pituitary also adapts pulse amplitude and frequency over time. This creates a self-limiting system: as IGF-1 rises into the upper-normal range, the increment from additional GHRH agonism diminishes. Exogenous rhGH bypasses this entirely, creating dose-dependent supraphysiological IGF-1 elevation with corresponding risks of insulin resistance, acromegaly-like soft-tissue changes, and theoretical long-term proliferative concerns.

Trial data: tesamorelin in HIV lipodystrophy and metabolic syndrome

Tesamorelin has the most robust clinical dataset of any GHRH analogue. In the NAIL (Normalization of Abdominal fat with tesamorelin) programme, two Phase 3 trials (LIPO-010 and LIPO-011) demonstrated significant visceral adipose tissue (VAT) reduction (approximately 15–18% from baseline) in HIV-positive adults with antiretroviral-associated lipodystrophy after 26 weeks of daily tesamorelin 2 mg subcutaneously. IGF-1 was restored to the normal range in most participants; fasting glucose changes were neutral, consistent with somatostatin-gated GH pulsatility preventing hyperinsulinaemic rebound.

More recently, investigator-led studies in metabolic syndrome and age-related GH deficiency (somatopause) have demonstrated tesamorelin-mediated reductions in intrahepatic lipid (as measured by MRS) — a finding consistent with GH-driven hepatic fatty-acid oxidation. These data position GHRH analogues as potential adjuncts to incretin-based pharmacology in patients with combined MASLD and visceral obesity.

Why this matters for next-generation research

The GHRH/somatotrope axis is increasingly viewed as a target for combination strategies alongside GLP-1R/GIPR agonists. GH-driven lipolysis and IGF-1-mediated lean mass preservation may help address the lean mass loss seen with aggressive caloric restriction from GLP-1R agonists (the STEP and SURMOUNT programmes both documented approximately 25–40% of total weight loss coming from lean tissue). A GHRH analogue providing physiological GH restoration could, in theory, bias body composition changes towards fat loss and lean mass maintenance — a hypothesis now being explored in combination design protocols.

GHRH axis mechanism